The Effect of Dopamine on Diabetic Retinopathy (Dopamine DR)
Diabetes
About this trial
This is an interventional treatment trial for Diabetes focused on measuring Ophthalmology
Eligibility Criteria
Inclusion Criteria
Participants with Diabetes Mellitus:
- Diagnosis of diabetes mellitus type-2
- HbA1c between 8 and 12%
Age-Matched Controls:
- Non-diabetic
Exclusion Criteria
Participants with Diabetes Mellitus:
- Currently taking dopamine-enhancing drugs (L-DOPA, bromocriptine)
- Currently taking nonselective monoamine oxidase (MAO) inhibitors
- Diagnosis of psychosis, Parkinson's disease, restless leg syndrome, major depression, confounding ocular disease (eg. visually significant cataract, glaucoma, macular degeneration, or retinitis pigmentosa)
- Pregnancy
Age-Matched Controls:
- Diabetes diagnosis
- Currently taking dopamine-enhancing drugs (L-DOPA, bromocriptine)
- Currently taking nonselective monoamine oxidase (MAO) inhibitors
- Diagnosis of psychosis, Parkinson's disease, restless leg syndrome, major depression, confounding ocular disease (eg. visually significant cataract, glaucoma, macular degeneration, or retinitis pigmentosa)
- Pregnancy
Sites / Locations
- Atlanta VA Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Other
Other
Diabetes Group - Low Dose Sinemet CR
Diabetes Group - High Dose Sinemet CR
Diabetes Group - No Electroretinogram (ERG) Delays
Age-Matched Controls
Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive low dose Sinemet CR twice daily for two weeks.
Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive high dose Sinemet CR twice daily for two weeks.
Participants with diabetes mellitus type-2 who do not have electroretinogram (ERG) delays. Participants in this group will have one baseline visit only.
Participants will serve as age-matched controls for participants with diabetes. This group will participate in the baseline, week 2, and week 4 visits only.